• 1
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:12021219.
  • 2
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:12211231.
  • 3
    Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:17051725.
  • 4
    Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:6871.
  • 5
    Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore). 1962;41:249276.
  • 6
    Ludwig J, Viggiano TR, McGill DB. et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434438.
  • 7
    Hamaguchi M, Kojima T, Takeda N. et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722728.
  • 8
    Willy Haukeland J, Konopski Z, Linnestad P, et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2005;40:14691477.
  • 9
    Cortez-Pinto H, De Moura MC, Day CP. Nonalcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2006;44:197208.
  • 10
    Diehl AM. Lessons from animal models of NASH. Hepatol Res. 2005;33:138144.
  • 11
    Sowers JR. Update on the cardiometabolic syndrome. Clin Cornerstone. 2001;4:1723.
  • 12
    Gill H, Mugo M, Whaley-Connell A, et al. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci. 2005;330:290294.
  • 13
    Den Boer M, Voshol PJ, Kuipers F, et al. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Tromb Vasc Biol. 2004;24:644649.
  • 14
    Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367372.
  • 15
    Ibdah JA, Perlegas P, Zhao Y, et al. Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology. 2005;128:13811390.
  • 16
    Diehl AM, Li ZP, Lin HZ, et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut. 2005;54:303306.
  • 17
    Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113121.
  • 18
    Caldwell SH, Oelsner DH, Iezzoni JC. et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664669.
  • 19
    Adams LA, Sanderson S, Lindor KD. et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132138.
  • 20
    Marbet UA, Bianchi L, Meury U. et al. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol. 1987;4:364372.
  • 21
    Matteoni CA, Younossi ZM, Gramlich T. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:14131419.
  • 22
    Bacon BR, Farahvash MJ, Janney CG. et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:11031109.
  • 23
    Cohen JA, Kaplan MM. The SGOT/SGPT ratio—an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24:835838.
  • 24
    Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:10181022.
    Direct Link:
  • 25
    Mofrad P, Contos MJ, Haque M. et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:12861292.
  • 26
    Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR. 1995;16:1633.
  • 27
    Saadeh S, Younossi ZM, Remer EM. et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology. 2002;123:745750.
  • 28
    Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986;220:8388.
  • 29
    Rozental P, Biava C, Spencer H. et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis. 1967;12:198208.
  • 30
    Andersen T, Gluud C, Franzmann MB. et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224229.
  • 31
    Hickman IJ, Jonsson JR, Prins JB. et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53:413419.
  • 32
    Dixon JB, Bhathal PS, Hughes NR. et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:16471654.
  • 33
    Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603608.
  • 34
    Harrison SA, Torgerson S, Hayashi P. et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:24852490.
    Direct Link:
  • 35
    Uygun A, Kadayifci A, Isik AT. et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537544.
  • 36
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:10081017.
  • 37
    Laurin J, Lindor KD, Crippin JS. et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic steatohepatitis: a pilot study. Hepatology. 1996;23:14641467.
  • 38
    Lindor KD, Kowdley KV, Heathcote EJ. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770778.
  • 39
    Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:12221232.